| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Caution against overoptimistic findings
|
Kouzan, S.
|
|
|
35 |
3 |
p. 330-331
|
artikel
|
| 2 |
Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
|
Moik, F.
|
|
|
35 |
3 |
p. 327
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
35 |
3 |
p. iii
|
artikel
|
| 4 |
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease ☆
|
Ledermann, J.A.
|
|
|
35 |
3 |
p. 248-266
|
artikel
|
| 5 |
European cancer mortality predictions for the year 2024 with focus on colorectal cancer
|
Santucci, C.
|
|
|
35 |
3 |
p. 308-316
|
artikel
|
| 6 |
Hit hard and remove treatment – this treatment strategy in Hodgkin Lymphoma promises less fatigue and less sick-leave
|
Glimelius, I.
|
|
|
35 |
3 |
p. 245-247
|
artikel
|
| 7 |
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial☆
|
Ferdinandus, J.
|
|
|
35 |
3 |
p. 276-284
|
artikel
|
| 8 |
Letter to the Editor regarding ‘Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study’ by Moik F, Riedl JM, and Ay C
|
Passaro, A.
|
|
|
35 |
3 |
p. 328-329
|
artikel
|
| 9 |
Letter to the editor regarding ‘Misclassified confounders in the second interim analysis of the MAGNITUDE trial’ by P. Chen, M. Liu, G.Y. Li, F. Sun, T. Li
|
Chi, K.N.
|
|
|
35 |
3 |
p. 329-330
|
artikel
|
| 10 |
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
|
Gouda, M.A.
|
|
|
35 |
3 |
p. 267-275
|
artikel
|
| 11 |
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
|
Piulats, J.M.
|
|
|
35 |
3 |
p. 317-326
|
artikel
|
| 12 |
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial ☆
|
Spring, L.M.
|
|
|
35 |
3 |
p. 293-301
|
artikel
|
| 13 |
Table of Contents
|
|
|
|
35 |
3 |
p. i-ii
|
artikel
|
| 14 |
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01) ☆
|
Saura, C.
|
|
|
35 |
3 |
p. 302-307
|
artikel
|
| 15 |
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer
|
Xie, W.
|
|
|
35 |
3 |
p. 285-292
|
artikel
|
| 16 |
VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)
|
Yue, D.
|
|
|
35 |
3 |
p. 332-333
|
artikel
|
Tijdschrift beschrijving